337 Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI

David Tougeron; Jean Francois Emile; Stephano Kim; Carole Monterymard; Marine Gilabert; BEZ Jérémie; Astrid Lievre; Laetitia Dahan; Pierre Laurent-puig; Laurent Mineur; ROmain Coriat; Jean Louis Legoux; Vincent Hautefeuille; Jean marc Phelip; Thierry Lecomte; Harry Sokol; Claude Capron; Claire Gallois; Violaine Randrian; Come Lepage; Julien Taieb

doi:10.1136/jitc-2020-SITC2020.0337

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PDF

Regular and young investigator award abstracts

Clinical trials in progress

337 Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password